Cheetah Medical, Inc.

Cheetah Medical, Inc. specializes in innovative fluid management solutions for healthcare, empowering clinicians with advanced technology to manage patient fluid status effectively. Founded in 2001 in Newton, US, Cheetah Medical, Inc. focuses on developing fluid management systems.

The company has executed 10 deals with the most recent being a TRADE SALE on September 10, 2019, where Baxter Health Enlon Products acquired Cheetah Medical for USD 190. 00 mn, potentially increasing by an additional USD 40. 00 mn based on clinical and commercial milestones. The acquisition closed in Q4 2019.

Cheetah Medical advances personalized fluid management through the Starling Fluid Management System, a non-invasive technology that provides healthcare professionals with accurate insights into patients' fluid status. The system facilitates dynamic assessments via fluid challenges, aiding in therapy optimization, particularly in critical care scenarios. The Starling system is marketed mainly to healthcare professionals in the US, including hospitals and acute care settings, especially during critical conditions like sepsis and COVID-19. Cheetah Medical generates revenue through the sale of the Starling Fluid Management System and associated educational resources, primarily through B2B transactions with hospitals and clinics.

Sales often involve direct purchases of the Starling system, complemented by subscriptions to ongoing educational resources for clinicians to maximize the system's effectiveness in patient care. Looking ahead, Cheetah Medical plans to leverage its acquisition by Baxter Health to enhance product development and market reach. The company aims to develop new products tailored for specific medical conditions and expand its market presence beyond the US into international territories. The recent funding from the TRADE SALE will support these initiatives, focusing on advancing technology and increasing market penetration.